ACE2 News and Research

RSS

Novel mutations in SARS-CoV-2 may explain high pathogenicity of COVID-19

Researchers in Korea and the United States have identified novel genetic variants that demonstrate the active mutational progression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Nov 2020

Bispecific sybodies show potential against SARS-CoV-2

As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.

12 Nov 2020

SARS-CoV-2-induces temporary loss of smell in mice

Now, a new study published on the preprint server bioRxiv in November 2020 presents the onset of olfactory dysfunction (loss of smell) in mice infected with the virus, examining this process at the cellular level. In doing so, this study throws more light on this curious symptom and COVID-19’s manifestations outside the lungs.

12 Nov 2020

Researchers assess risks posed by SARS-CoV-2 to Antarctica wildlife

Researchers have assessed risks posed by the ongoing COVID-19 pandemic on Antarctica wildlife.

12 Nov 2020

Rhesus monkeys and cats potential spillover reservoirs for COVID-19 virus

A team of researchers from Switzerland, Costa Rica and Germany has conducted a study showing which animal species could potentially serve as spillback reservoirs of severe acute repertory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

12 Nov 2020

Low prevalence of SARS-CoV-2 specific antibodies in Lubbock, Texas

A recent study published in the Journal of Primary Care and Community Health has assessed the prevalence of antibodies developed specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in front-line workers in Lubbock, Texas. According to the study findings, immunoglobulin G (IgG)-specific anti-SARS-CoV-2 antibodies have been detected in only 0.73% of the participants.

11 Nov 2020

Research tracks humoral immunity response over eight months post COVID-19 infection

Researchers from Chongqing Medical University have tried to answer one of the burning questions regarding the longevity of immune response to coronavirus disease 2019 (COVID-19): How long does immunity last after infection? Their study looked at the lasting effects and continued immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over eight months after recovery from the infection.

11 Nov 2020

Nafamostat mesylate initially reduces SARS-CoV-2 viral loads in hamsters, study finds

Researchers have found that nafamostat mesylate, when injected in the nasal cavity of Syrian hamsters, can decrease initial SARS-CoV-2 viral loads in their nose. However, this effect was temporary and further testing is required to determine clinically significant effects. The research group's findings are available on the preprint server bioRxiv*.

11 Nov 2020

Endothelial cells resistant to SARS-CoV-2 infection

A team of scientists from Imperial College London has conducted a series of in vitro studies to investigate the susceptibility of endothelial cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative pathogen of coronavirus disease 2019 (COVID-19).

10 Nov 2020

Identifying SARS-CoV-2 spike protein mutations resistant to antibodies

Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.

10 Nov 2020

ACE2 and TMPRSS2 not the only virus-receptors to mediate SARS-CoV-2 entry

However, a recent study published on the preprint server bioRxiv in November 2020 uncovers the major role played by the N-terminal domain of the SARS-CoV-2 virus in host infection. This could be of great use in measuring the usefulness of antibodies used in convalescent plasma therapy for COVID-19.

9 Nov 2020

Immune-evading variants can emerge in SARS-CoV-2, researchers warn

An international team of researchers has shown that a mutation within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) – enables the pathogen to evade antibody-mediated immunity while maintaining replication fitness and increasing viral loads.

9 Nov 2020

Study shows SARS-CoV-2 direct heart muscle cell infection, cell death, loss of contractility

In the study, published on the pre-print journal bioRxiv, the researchers revealed that SARS-CoV-2-infected EHTs manifested the typical characteristics of myocarditis or heart inflammation. These include the stimulation of immune cells, heart cell death, and decreased contractile force generation.

8 Nov 2020

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

A team of researchers in Singapore, led by Dr. Joe Yeong, and Prof. Tony Kiat Hon Lim, have reported the presence of residual SARS-CoV-2 ribonucleic acid (RNA) – the virus' genetic material – in stool samples and gastrointestinal tissues from patients recovering from the coronavirus disease 2019 (COVID-19).

8 Nov 2020

Innate immunity key to limiting viral load in COVID-19 cases

As the coronavirus disease 2019 (COVID-19) pandemic continues to cause many difficulties for public health authorities, research is ongoing to understand how the virus can cause fatal effects on those infected and thereby suggest effective preventive and therapeutic measures against it.

8 Nov 2020

Universal nanoparticle platform may help in rapid development of a COVID-19 vaccine

A research group in China recently published a paper on the pre-print server bioRxiv* that reports the performance of a potentially universal nanoparticle platform that may prove useful for the rapid development of a COVID-19 vaccine, as well as other vaccines in the future.

8 Nov 2020

Reducing the airborne transmission risk for SARS-CoV-2

Rapid Reviews: COVID-19 (RR:C19), an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints, is currently soliciting reviews of the following COVID-19 preprints.

6 Nov 2020

Researchers identify antibodies that prevent SARS-CoV-2 from infecting human cells

The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2.

5 Nov 2020

Green tea and some fruit juices inhibit SARS-CoV-2 in vitro

Green tea, chokeberry juice, and pomegranate juice killed flu and SARS-CoV-2 viruses when incubated with the viruses in vitro. Thus, oral rinsing using these might be effective in preventing COVID-19.

5 Nov 2020

Computational study reveals SARS-CoV-2 spike protein structural stability

Using dynamic contact maps and energy differences between different conformations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (or S-protein), an international team of researchers have recently published an article on the bioRxiv preprint server showing the different stable conformations of the spike protein.

4 Nov 2020